Press Releases

All Releases
Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR
Apr 9, 2014
PDF 15.1 KB
Nektar Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
Feb 26, 2014
PDF 26.1 KB
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2013 on Wednesday, February 26, 2014, After Close of U.S.-Based Financial Markets
Feb 19, 2014
PDF 7.9 KB
Nektar Therapeutics Prices Public Offering of Common Stock
Jan 22, 2014
PDF 5.9 KB
Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock
Jan 21, 2014
PDF 6.4 KB
Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Fluorouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium
Jan 18, 2014
PDF 13.7 KB
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Jan 14, 2014
PDF 15.5 KB
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain
Jan 14, 2014
PDF 14.9 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 8, 2014
PDF 7.2 KB
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
Nov 19, 2013
PDF 10.5 KB
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
Nov 13, 2013
PDF 261.3 KB
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Nov 7, 2013
PDF 25.1 KB
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
Oct 30, 2013
PDF 9.9 KB
Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Oct 24, 2013
PDF 200.2 KB
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day
Oct 8, 2013
PDF 11.7 KB
Nektar to Host Investor and Analyst R&D Day in New York City
Oct 2, 2013
PDF 9.2 KB
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Sep 30, 2013
PDF 8.7 KB
Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee
Sep 26, 2013
PDF 17.0 KB
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
Aug 8, 2013
PDF 27.4 KB
Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
Aug 1, 2013
PDF 7.6 KB
Showing 1-20 of 184 Page: 1 2 3 ... 10  Next 20
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide